Jinlida granules alleviate podocyte apoptosis and mitochondrial dysfunction via the AMPK/PGC‑1α pathway in diabetic nephropathy
International Journal of Molecular Medicine · 05.12.2024 · 55 (2)
DOI: 10.3892/ijmm.2024.5467 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 05.12.2024. Verfasst von Shengnan Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien‑I Memorial Hospital and Tianjin Institute of …. Hauptthemen laut MEDLINE: Podocytes, Diabetic Nephropathies, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Apoptosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Traditional Chinese Medicine (TCM) has demonstrated promising efficacy in managing and preventing the early‑stage diabetic nephropathy (DN). Although the exact mechanisms remain elusive, clinical evidence has suggested that Jinlida granules (JLD) are beneficial in improving renal function among patients with DN. The present study aimed to elucidate the effect of JLD on DN and the underlying molecular mechanism. Therefore, podocyte apoptosis was evaluated using flow cytometry and TUNEL staining, while mitochondrial morphology and function were assessed using transmission electron microscopy, MitoTracker, JC‑1 and reactive oxygen species staining. RNA sequencing analysis was performed to elucidate the mechanism underlying the effect of JLD on DN. Additionally, to investigate the role of peroxisome proliferator‑activated receptor‑γ co‑activator‑1α (PGC‑1α) in mitigating JLD‑induced mitochondrial dysfunction and podocyte apoptosis, MPC5 cells were transfected with the corresponding small interfering RNA constructs. The results showed that JLD effectively improved renal function and mitigated podocyte injury, as well as ameliorated mitochondrial dysfunction and inhibited apoptosis in db/db mice. In vitro experiments further revealed that JLD exerted a protective effect via inhibiting mitochondrial fission and apoptosis in high glucose‑treated podocytes. Furthermore, JLD enhanced the phosphorylation of adenosine monophosphate‑activated protein kinase (AMPK), thus promoting the expression of PGC‑1α, eventually improving apoptosis and mitochondrial homeostasis. Overall, the current study revealed that JLD could improve mitochondrial homeostasis and reduce cell apoptosis in podocytes via activating the AMPK/PGC‑1α pathway, thus providing a theoretical foundation for the clinical management of DN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien‑I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, P.R. China.
Zitieren
APA
Sun, S., Yang, S., Cheng, Y., Fang, T., Qu, J., Tian, L., Zhang, M., Wu, S., Sun, B., & Chen, L. (2024). Jinlida granules alleviate podocyte apoptosis and mitochondrial dysfunction via the AMPK/PGC‑1α pathway in diabetic nephropathy. International Journal of Molecular Medicine, 55(2). https://doi.org/10.3892/ijmm.2024.5467
Vancouver
Sun S, Yang S, Cheng Y, Fang T, Qu J, Tian L, et al. Jinlida granules alleviate podocyte apoptosis and mitochondrial dysfunction via the AMPK/PGC‑1α pathway in diabetic nephropathy. International Journal of Molecular Medicine. 2024;55(2). doi:10.3892/ijmm.2024.5467
BibTeX
@article{Sun2024,
author = {Sun, Shengnan and Yang, Shurong and Cheng, Ying and Fang, Ting and Qu, Jingru and Tian, Lei and Zhang, Man and Wu, Shi and Sun, Bei and Chen, Liming},
title = {Jinlida granules alleviate podocyte apoptosis and mitochondrial dysfunction via the AMPK/PGC‑1α pathway in diabetic nephropathy},
journal = {International Journal of Molecular Medicine},
year = {2024},
volume = {55},
number = {2},
doi = {10.3892/ijmm.2024.5467}
}
EUVIMED